Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

atment. PEGASYS is also contraindicated in hepatic decompensation with Child-Pugh score greater than or equal to 6 in cirrhotic CHC patients coinfected with HIV before or during treatment. PEGASYS is also contraindicated in neonates and infants because it contains benzyl alcohol. Benzyl alcohol is associated with an increased incidence of neurological and other complications in neonates and infants, which are sometimes fatal. PEGASYS and COPEGUS therapy is additionally contraindicated in patients with a hypersensitivity to COPEGUS or any of its components, in women who are pregnant, men whose female partners are pregnant, and patients with hemoglobinopathies (eg, thalassemia major, sickle-cell anemia).

COPEGUS THERAPY SHOULD NOT BE STARTED UNLESS A REPORT OF A NEGATIVE PREGNANCY TEST HAS BEEN OBTAINED IMMEDIATELY PRIOR TO INITIATION OF THERAPY. Women of childbearing potential and men must use two forms of effective contraception during treatment and during the 6 months after treatment has concluded. Routine monthly pregnancy tests must be performed during this time. If pregnancy should occur during treatment or during 6 months post-therapy, the patient must be advised of the significant teratogenic risk of COPEGUS therapy to the fetus. Healthcare providers and patients are strongly encouraged to immediately report any pregnancy in a patient or partner of a patient during treatment or during 6 months after treatment cessation to the Ribavirin Pregnancy Registry at 1-800-593-2214.

Chronic hepatitis C (CHC) patients with cirrhosis may be at risk of hepatic decompensation and death when treated with alpha interferons, including PEGASYS. During treatment, patients' clinical status and hepatic function should be closely monitored, and PEGASYS treatment should be immediately discontinued if decompensation (Child-Pugh score greater than or equal to 6) is observed.

The most common adverse events reported for PEGASYS and COPEGUS combination therapy observed
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... IRVINE, Calif. , Dec. 19, 2014 /PRNewswire/ ... today that Siddhartha Kadia, Ph.D. has joined the ... and Chief Executive Officer and a director of ... high-precision laboratory testing, evaluation and analytical services to ... Prior to joining Evans Analytical Group, ...
(Date:12/19/2014)... 19, 2014   Hospira, Inc. (NYSE: ... drugs and infusion technologies, today announced that the company ... Conference on Wednesday, Jan. 14, 2015, in San ... begin at 10:30 a.m. Pacific time on Wednesday, Jan. ... parties through a live audiocast accessible via the Investor ...
(Date:12/19/2014)... and CARDIFF-BY-THE-SEA, Calif. , Dec. ... SRNE ;  Sorrento), an oncology company developing ... Conkwest, Inc., a privately-held immuno-oncology company developing proprietary ... cell-line based therapy, announced today that the companies ... develop next generation CAR-TNK™ (pronounced as "Car-Tank") immunotherapies ...
Breaking Medicine Technology:Siddhartha Kadia, Ph.D. Joins Board of Directors of Newport Corporation 2Sorrento and Conkwest Announce Exclusive Global Collaboration 2Sorrento and Conkwest Announce Exclusive Global Collaboration 3Sorrento and Conkwest Announce Exclusive Global Collaboration 4Sorrento and Conkwest Announce Exclusive Global Collaboration 5
... Conference Call Scheduled for 9:00 AM ET ... Dendreon Corporation (Nasdaq:,DNDN) announced today that it ... Phase 3, randomized, double-blind, placebo-controlled IMPACT,(IMmunotherapy for ... trial designed to assess the safety and ...
... Oct. 6 Dendreon Corporation (Nasdaq:,DNDN) will host ... at 9:00 AM,ET (6:00 AM PT) to review ... IMPACT,(IMmunotherapy for Prostate AdenoCarcinoma Treatment, also known as ... cellular immunotherapy for the treatment of advanced prostate,cancer., ...
Cached Medicine Technology:Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 2Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 3Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial 4Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial 2
(Date:12/19/2014)... Tampa, FL (PRWEB) December 19, 2014 ... Celliant Revitalizing Bedsheets are now available. Celliant, the ... in both sheets and pillowcases. , There are ... clinically proven additional circulation, increased oxygenation and balanced ... quality, faster healing and pain relief; enhanced athletic ...
(Date:12/19/2014)... Santa Rosa, CA (PRWEB) December 19, 2014 ... 2x4 and 5x5 SuperClone Rooms. SuperCloset continues to offer ... grow solutions. Pair one of the new SuperClone Rooms ... truly professional, perpetual, and turnkey indoor hydroponic grow room ... cloner in the world, SuperCloset’s SuperPonic SuperCloner 50 ...
(Date:12/19/2014)... An evening dress is perfect for any occasion ... a distinguished dresses retailer, has unveiled its new selection of ... this great shopping platform. Customers can view more ... Discount-Dress.com has been accepted and praised by customers for many ... stage for clients. In order to expand its market share, ...
(Date:12/19/2014)... warns parents that buying an older car for their teens may ... drivers killed in the United States between 2008 and 2012 were ... lacked important safety features that are available on newer cars, the ... were in cars at least six years old, 34 percent were ... cars 11 to 15 years old, and 17 percent were in ...
(Date:12/19/2014)... (HealthDay News) -- Potentially illness-causing E. coli bacteria were ... markets, according to a new study. Researchers checked ... 13 farmers markets in Los Angeles and Orange counties ... almost 150 samples tested, 24 percent were positive for ... to the researchers. Both types of bacteria can ...
Breaking Medicine News(10 mins):Health News:Energy Textiles Launches Celliant Revitalizing Bedsheets 2Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2Health News:Attractive Evening Dresses Announced by Discount-Dress.com 2Health News:Older Cars a Bad Choice for Younger Drivers 2Health News:E. Coli Germs Found on Farmers Market Herbs 2
... Calif., Sept. 17 The Los Angeles,Area Chamber ... proposal which includes a 4 percent payroll fee ... not already contribute at least that much,to providing ... Chamber,Board of Directors urged Governor Schwarzenegger and other ...
... Offices of Howard G.,Smith announces that a securities class ... purchased the common stock of LCA-Vision Inc.,("LCA-Vision" or the ... July 30, 2007 (the "Class Period"). The class action ... the Southern District of Ohio. The Complaint alleges ...
... Expanded Solutions to Medical Device and,Diagnostics Industries, ... (SBI),announced today that it has entered into a ... (Popper). Popper supplies a variety of specialty,needle and ... The combination will create the world,s leading cutting ...
... N.J., Sept. 17 Akers Biosciences,Inc. (LSE: AKR) ... screening and testing products, is pleased to announce ... States Army for the purchase of its,BreathScan alcohol ... and,is deliverable beginning immediately. The Company has ...
... in National Clean Hands Week survey-, PHILADELPHIA, Sept. ... Coalition,s "Cleanest Hands in America" survey,residents of the Philadelphia ... hygiene practices of individuals living in the U.S. top ... ranked #23 ... one above,Portland, OR #24 and two ...
... A new study by researchers at the University of Southern ... , Researchers found that a storyline on the primetime ... and healthy eating habits had a positive impact on the ... study, published in the Sept. 14 Journal of Health Communication ...
Cached Medicine News:Health News:Los Angeles Area Chamber of Commerce Endorses Governor Schwarzenegger's Health Care Proposal 2Health News:Akers Biosciences, Inc. 'ABI' or the 'Company' Receipt of Further United States Military Contracts 2Health News:ER episode impacts viewers' health knowledge and behavior 2
... brings new freedom and portability to ... and excellence that are the hallmark ... eyecare practitioners a simple, affordable, and ... utilizes the same proven technology of ...
The Electric H-Base Table is for heavier instruments, or for those who prefer electric elevation. The electric table easily accepts a slit lamp, a single tabletop, or a double tabletop, just as the M...
... Ideal for satellite clinics or ... high value, the Debut stand is ... steel construction and molded composite body ... heavy-duty, counterbalanced slit-lamp arm--one of two ...
... a choice of two feature-packed projectors ideal for ... halogen bulb for longer life -- up to ... Projector offers a lower initial cost with an ... extended bulb life. And both provide exceptionally even ...
Medicine Products: